Neurodegenerative and neuropsychiatric disease mechanisms
Scientific/business appraisal of life science start ups
Single-locus genomic analysis
Synaptic Plasticity
Enzyme Assays
Pacbio
Genome Browser
Illumina
Enzymatic Assays
Cell Biology
Kinases
Western Blotting
Homer
Neurodegeneration
Proteomics
Glutamate Receptors
Phosphorylation
PCR
Cell Culture
Single Cell Seq
Intracellular Signaling
Immunocytochemistry
Bowtie1&2
Scientific Writing
Phosphatases
Subcloning
RNAseq
Sra
In Vivo Mouse Models
Molecular Biology
Single Locus Genomic Analysis
Agilent
Voltage Gated Ion Channels
Ataxia
Primary Cultures
Ampar
Additional Ngs Platforms
Nmdar
Viral Vectors
Protein Synthesis
Homeostatic Plasticity
Dnaseq
Chip Seq
Transgenic Mice
Biochemistry
Neuronal Culture
Fret
Protein Chemistry
Benjamin Siddoway Summary
Benjamin Siddoway, based in California, United States, is currently a Founder and CEO at Seq Therapeutics. Benjamin Siddoway brings experience from previous roles at Bristol Myers Squibb, Vertex Pharmaceuticals and Sanford Burnham Prebys Medical Discovery Institute. Benjamin Siddoway holds a 2005 - 2011 Doctor of Philosophy (PhD) in Cellular and Molecular Neurobiology @ LSU Health Sciences Center New Orleans. With a robust skill set that includes AMPAR, NMDAR, Voltage gated ion channels, ChIP-seq, DNAseq, RNAseq, Single-cell seq, Competitive and freedom to operate analysis, Comprehensive knowledge of molecular toolsets, Custom NGS Assay Design and Implementation and more. Benjamin Siddoway has 1 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Benjamin Siddoway?
Find contact details for 700 million professionals.